The METTL3/TGF-β1 signaling axis drives osteosarcoma tumorigenesis by enhancing CAFs differentiation, offering a novel therapeutic target to combat advanced metastatic disease [239]. The gene discussed is METTL3; the disease is osteosarcoma.